GYRE THERAPEUTICS, INC. (GYRE): Nasdaq/NYSE listing notice — Gyre Therapeutics regains Nasdaq compliance on audit committee composition

GYRE THERAPEUTICS, INC.

Received Nasdaq letter on March 22, 2024, confirming regained compliance with Listing Rule 5605.
Non-compliance was previously disclosed on Jan 17, 2024, due to lack of three independent directors.
Compliance restored on March 20, 2024, with appointment of Rodney Nussbaum to Audit Committee.
No further deficiencies; shares continue trading on Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GYRE THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding audit committee (rules 5605).

Exchange: nasdaq
Notice: compliance regained
Deficiency: audit committee
Rules: 5605

Exact text from the filing

March 22, 2024, Gyre Therapeutics, Inc. (the “ Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the audit committee composition requirements as set forth in Nasdaq Listing Rule 5605 for continued listing on The Nasdaq Capital Market. As previously disclosed, on January 17, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5605 because its Audit Committee was not comprised of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)). The C

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-015318

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.